GlassScriptPhysician profile
Jeffrey A Kohn
NPI 1235218918
$871.44
in general payments reported to CMS, 2019-2025
17 companies · $80.11 in 2025
The $80.11 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $48.29 · 2023: $19.00 · 2025: $80.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $121.82 | 2019-2020 | |
| Amarin Pharma, INC. | $84.21 | 2019 | |
| Abbvie INC. | $67.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.35 | 2019 | |
| Pfizer INC. | $64.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.65 | 2019 | |
| Heartflow, INC. | $46.91 | 2025 | |
| Sanofi Pasteur INC. | $42.48 | 2019 | |
| Novo Nordisk INC | $33.20 | 2025 | Wegovy |
| Abbott Laboratories | $24.87 | 2019 | |
| Gilead Sciences, INC. | $23.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.44 | 2019 | |
| Biotronik INC. | $19.23 | 2019 | |
| Smith+Nephew, INC. | $19.00 | 2023 | Grafix Pl |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.97 | 2019 | |
| Glaxosmithkline, LLC. | $15.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.